CGEN

This article first appeared on GuruFocus. Cash Position: Approximately $125.3 million in cash equivalents, short-term bank deposits, and marketable securities as of June 30, 2026. Revenue: Approximately $2.6 million for Q2 2026, compared to $1.3 million in Q2 2025. R&D Expenses: Approximately $6.3 million for Q2 2026, compared to $5.6 million in Q2 2025. G&A Expenses: Approximately $2.3 million for Q2 2026, compared to $2.2 million in Q2 2025. Net Loss: Approximately $7.0 million, or $0.07 per basic and diluted share, for Q2 2026, compared to a net loss of $7.3 million, or $0.08 per share, in Q2 2025. Cash Runway: Expected to fund operating plans into 2029, assuming no further cash inflows. Warning! GuruFocus has detected 4 Warning Signs with CGEN. Is CGEN fairly valued? Test your thesis with our free DCF calculator. Release Date: August 03, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Compugen Ltd (NASDAQ:CGEN) is advancing its wholly-owned COM701 program with the MyOvarian trial on track for an interim analysis by Q1 2027, targeting a high unmet need in platinum-sensitive ovarian cancer. AstraZeneca's continued investment in rilvegostomig, including a new Phase III trial in urothelial carcinoma, underscores confidence in the asset and its potential to generate milestones and royalties for Compugen Ltd (NASDAQ:CGEN). New data from AstraZeneca's GEMINI hepatobiliary study showed a median overall survival of 16.8 months in first-line biliary tract cancer, exceeding historical benchmarks of less than 13 months. Compugen Ltd (NASDAQ:CGEN) maintains a solid cash position of $125.3 million, with a runway expected to fund operations into 2029, supporting ongoing clinical and pipeline activities. The company's AI-driven platform, Unigen, continues to deliver innovative targets, with GS0321 (licensed to Gilead) progressing as planned in Phase I dose escalation, offering additional upside through milestones and royalties. Compugen Ltd (NASDAQ:CGEN) revised its estimated median PFS for the placebo control arm in the MyOvarian trial down to approximately four months, reflecting a more heavily pretreated patient population and potentially higher hurdle for demonstrating COM701's benefit. The MyOvarian trial is not powered to show a statistical difference, and the interim analysis relies on a relatively small sample size (40 patients on COM701 vs. 20 on placebo), which may limit the strength of conclusions. No regulatory interactions with the FDA have occurred for the MyOvarian trial, and the path to approval remains uncertain, with the company only noting alignment with Project Front Runner guidelines. Phase III readouts for rilvegostomig are not expected until after 2027, meaning potential milestones and royalties from AstraZeneca are likely several years away. The company's net loss of $7 million in Q2 2026, while slightly improved year-over-year, reflects ongoing R&D and G&A expenses with no near-term product revenue, relying on partnerships for cash inflows. Q: What is the company's updated expectation for the placebo control arm in the MyOvarian trial, and what data supports this revised assumption?A: Michelle Mahler, Chief Medical Officer, explained that the company has adjusted its estimate for the placebo control arm's median progression-free survival (PFS) to approximately four months. This revision is based on emerging data from two European trials (Tadova and OREO) in relapsed platinum-sensitive ovarian cancer, which showed a median PFS of 2.8 months in their control arms. While those trials included more heavily pre-treated patients (including those with liver metastases and stable disease), the company believes the actual benchmark for its trial lies between the historical 5.5 months from PARP inhibitor registration trials and the 2.8 months from these newer studies, leading to the ~4-month estimate. Q: Has the company had any interactions with the FDA regarding a potential expedited or accelerated approval path for COM701 based on the MyOvarian trial?A: Michelle Mahler, Chief Medical Officer, stated that the company has not yet had a formal meeting with the FDA. However, the trial was designed in alignment with FDA guidelines, including the Project Front Runner initiative and the use of a Bayesian trial design. The company is confident that with robust data, it will be able to have productive regulatory engagements to discuss potential approval pathways. Q: With AstraZeneca now running 12 Phase III trials for rilvegostomig, which study might yield the earliest data readout, and does the new trial change the milestone schedule?A: Eran Ophir, President and CEO, clarified that the addition of the new Phase III trial (Tropion-Urothelial 04) does not alter the existing agreement terms or the milestone schedule. Regarding data readouts, the company can only refer to AstraZeneca's public guidance, which indicates that formal Phase III readouts are expected after 2027. While interim analyses could occur earlier, the official timeline for late-stage data remains post-2027. Q: Could the MyOvarian trial data readout potentially occur before the end of 2026, and what biomarkers will be evaluated alongside the PFS outcome?A: Eran Ophir, President and CEO, confirmed that the company is maintaining its guidance for an interim analysis by Q1 2027, despite the updated placebo assumptions. Michelle Mahler, Chief Medical Officer, added that PFS is the primary readout, and there is no specific biomarker selection strategy. The trial excludes patients with liver metastases, and exploratory biomarker analyses will be conducted when the data is unblinded. Q: What is the company's level of confidence in the revised four-month placebo PFS assumption, and what is known about the patient populations in the cited trials?A: Michelle Mahler, Chief Medical Officer, detailed that the two referenced trials (Tadova and OREO) were European studies that did not cap prior lines of treatment, included patients with stable disease, and allowed enrollment of patients with liver metastases. These factors made the populations more heavily pre-treated than the MyOvarian trial. Eran Ophir, President and CEO, emphasized that while the placebo assumption is important for planning, the critical comparison is the randomized, blinded data from the trial itself, which will definitively assess COM701's monotherapy activity. Q: What is the current status of the GS0321 (COM503) Phase I trial, and are there plans to present dose-escalation data?A: Eran Ophir, President and CEO, noted that due to the partnership arrangement with Gilead, the company cannot disclose specific details. However, he confirmed that the trial is progressing as planned, with dose escalation ongoing in both monotherapy and combination with a PD-1 inhibitor, as well as backfill cohorts in monotherapy. He indicated that it is still early for data disclosure, as 18 months into a Phase I study is typically too soon for reporting. Q: How does the company define "clinically meaningful success" for the MyOvarian trial's interim analysis?A: Eran Ophir, President and CEO, explained that success is defined as COM701 helping patients remain progression-free for at least six months after platinum-based chemotherapy. Achieving this threshold would maintain patients' platinum-sensitive status for longer, delay the transition to platinum-resistant disease, and provide a valuable recovery break from chemotherapy, thereby improving quality of life and preserving additional treatment options. Q: What is the company's cash position and expected runway following the second quarter of 2026?A: David Silberman, Chief Financial Officer, reported that the company ended Q2 2026 with approximately $125.3 million in cash, equivalents, and marketable securities. Assuming no further cash inflows, this runway is expected to fund operating plans into 2029, supporting the advancement of the MyOvarian trial, the GS0321 clinical program, and continued investment in the early-stage pipeline. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management is focusing on COM701 as a potential first-in-class anti-PVRIG antibody, specifically targeting the maintenance setting in platinum-sensitive ovarian cancer where no approved options exist. The MAIA-ovarian trial design utilizes a placebo control to isolate the specific clinical activity of COM701 monotherapy, avoiding the confounding effects of combination treatments. Performance attribution for the PVRIG pathway is driven by its differentiated biology compared to PD-1 and TIGIT, particularly its high expression in ovarian cancer and previously observed durable responses. AstraZeneca's initiation of a 12th Phase III trial for rilvegostomig in urothelial carcinoma signals sustained confidence in the asset as a foundational immuno-oncology backbone. The collaboration with Gilead on GS-0321 (anti-IL-18BP) is progressing through dose escalation, aiming to harness cytokine biology while overcoming historical limitations of direct cytokine administration. Compugen maintains a disciplined, data-driven approach to discovery via its Unigen AI platform, which focuses on uncovering novel human disease biology rather than optimizing known pathways. Interim analysis for the MAIA-ovarian trial, including median progression-free survival data, is on track for completion by the first quarter of 2027. Management has revised the estimated median progression-free survival for the MAIA control arm to approximately 4 months, down from 5.5 months, based on emerging external data from the TEDOVA and OReO trials. Clinically meaningful success for COM701 is defined as maintaining patients in a platinum-sensitive state for at least 6 months, delaying the transition to more intensive chemotherapy. Cash runway is projected to fund operations into 2029, assuming no further cash inflows, providing flexibility to advance the core pipeline and early-stage discovery. AstraZeneca has guided that Phase III results for rilvegostomig are generally expected after 2027, though interim analyses remain a possibility. The MAIA-ovarian trial is an exploratory study and is not powered to demonstrate statistical significance for registrational purposes at this stage. Patient eligibility for the MAIA trial excludes those with liver metastases to enrich for specific clinical attributes and potentially improve outcomes. Compugen remains eligible for $195 million in future milestones from AstraZeneca and up to $758 million from Gilead, plus tiered royalties on both programs. Revenue recognition in Q2 2026 ($2.6 million) primarily reflects the amortization of upfront and IND milestone payments from the Gilead license agreement. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management adjusted the benchmark from 5.5 months to approximately 4 months after reviewing recent European studies (TEDOVA and OReO) where control arms showed PFS of 2.8 months. The adjustment accounts for the MAIA population being less heavily pretreated than those in the cited European studies while acknowledging that historical registration data may now be outdated. The program is currently in dose escalation for both monotherapy and PD-1 combinations, including backfill cohorts at higher doses. Management indicated it is likely too early for data reporting given the 18-month duration of the Phase I study compared to industry benchmarks. While no formal FDA meetings have occurred yet, the MAIA trial was designed following FDA Project FrontRunner and Bayesian guidelines to facilitate future engagement. Robust data from the current exploratory trial could inform a formal registration path and establish COM701 as a combination backbone.

Interested in Compugen Ltd.? Here are five stocks we like better. COM701’s MAIA-ovarian trial continues enrolling, with an interim analysis including median progression-free survival data expected by Q1 2027. Management estimates the placebo arm’s median progression-free survival at about four months and said a clear benefit could help inform a potential registration strategy, although the exploratory study is not powered for registrational success. AstraZeneca expanded development of rilvegostomig, adding a 12th Phase III trial in high-risk muscle-invasive urothelial cancer. Compugen remains eligible for $195 million in milestones and tiered royalties, while AstraZeneca has cited potential peak-year revenue above $5 billion. Compugen reported approximately $125.3 million in cash and investments at June 30, 2026, and expects its cash runway to extend into 2029 without additional inflows. Second-quarter revenue rose to $2.6 million, while net loss narrowed to about $7 million from $7.3 million a year earlier. Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029. President and Chief Executive Officer Eran Ophir described the quarter as one of “steady advancement,” citing progress across the company’s clinical programs, collaborations and early-stage discovery activities. → Lost in Space: Why Aerospace Valuations Are Plummeting Right Now Compugen’s lead wholly owned program, COM701, is being evaluated in the MAIA-ovarian trial as a maintenance monotherapy for patients with second- and third-line relapsed platinum-sensitive ovarian cancer. The randomized, placebo-controlled adaptive platform study is assessing the potential first-in-class anti-PVRIG antibody in a setting where the company said there is no approved maintenance treatment option. The company expects an interim analysis containing median progression-free survival data by the first quarter of 2027. Ophir said Compugen presented a trial-in-progress poster at the ESMO Gynaecological Cancers Congress that outlined the biological and clinical rationale for COM701, including PVRIG’s differentiated biology relative to PD-1 and TIGIT, its expression in ovarian cancer, and prior observations of durable responses in heavily pretreated platinum-resistant patients. → MarketBeat Week in Review – 07/27- 07/31 Compugen now estimates that median progression-free survival in MAIA-ovarian’s placebo arm could be approximately four months. Chief Medical Officer Michelle Mahler said the estimate reflects emerging results from the European TADPOLE and ORION studies, whose placebo arms showed median progression-free survival of 2.8 months in more heavily pretreated patient populations. Those external studies allowed patients with stable disease, liver metastases and multiple prior treatments with bevacizumab or PARP inhibitors, Mahler said. Compugen’s prior benchmark had been based on older PARP inhibitor registration studies, where median progression-free survival was approximately five and a half months. → GE HealthCare Stock Climbs on Vital Diagnostics Demand Management said the MAIA-ovarian trial remains blinded and that the ultimate assessment will compare 40 patients receiving COM701 monotherapy with 20 patients in the placebo arm. The company defines clinically meaningful success at the interim analysis as helping patients remain progression-free for at least six months following platinum-based chemotherapy. Ophir said a clear prolongation of progression-free survival could inform a registration path for COM701, though MAIA is exploratory and is not powered as a registrational trial to demonstrate a statistical difference between treatment groups. During the question-and-answer session, Mahler said Compugen has not yet met with the FDA regarding whether MAIA-ovarian alone could support an expedited or accelerated approval path. She said the study design incorporated FDA guidance, including elements aligned with Project FrontRunner and Bayesian trial-design recommendations. AstraZeneca is advancing rilvegostomig, a PD-1/TIGIT bispecific antibody whose TIGIT component is derived from Compugen’s COM902 program. Ophir said AstraZeneca recently added a 12th phase III rilvegostomig trial, TROPION-Urothelial-04, in high-risk muscle-invasive urothelial carcinoma. That trial will evaluate rilvegostomig combined with Dato-DXd in the adjuvant setting against standard of care. Compugen said the study follows phase II data from TROPION-PanTumor03, in which the combination showed encouraging efficacy and manageable safety in metastatic urothelial carcinoma. Ophir also highlighted updated data from AstraZeneca’s GEMINI-Hepatobiliary study in first-line advanced biliary tract cancer. The reported overall survival figure was 16.8 months for rilvegostomig in combination with chemotherapy, compared with historical first-line studies cited by Compugen showing survival of less than 13 months. The company noted that longer follow-up and randomized phase III data will be needed to validate the findings. AstraZeneca has previously guided to non-risk-adjusted peak-year revenue potential of more than $5 billion for rilvegostomig, according to Compugen. Compugen remains eligible for $195 million in future milestones and up to mid-single-digit tiered royalties. Management said AstraZeneca’s formal guidance places phase III readouts after 2027, while noting interim analyses could potentially occur earlier. Compugen said Gilead’s phase I dose-escalation study of GS-0321, formerly COM503, continues as planned. GS-0321 is an anti-IL-18 binding protein antibody licensed to Gilead. Ophir said the study includes monotherapy and PD-1 combination dose escalation, as well as monotherapy backfill cohorts. Compugen has received $90 million from Gilead related to the asset and remains eligible for up to $758 million in additional milestone payments, plus single-digit to low-double-digit tiered royalties. Cash, cash equivalents, short-term bank deposits and marketable securities totaled approximately $125.3 million as of June 30, 2026. Second-quarter revenue was approximately $2.6 million, compared with $1.3 million a year earlier, reflecting recognition of portions of Gilead upfront and IND milestone payments. Research and development expense was approximately $6.3 million, up from $5.6 million in the prior-year period. General and administrative expense was approximately $2.3 million, compared with $2.2 million a year earlier. Net loss was approximately $7 million, or $0.07 per basic and diluted share, versus a loss of approximately $7.3 million, or $0.08 per share, in the second quarter of 2025. Chief Financial Officer David Silberman said the company expects its cash runway, assuming no further cash inflows, to support operating plans into 2029, including MAIA-ovarian, GS-0321 clinical progress and investment in its early-stage pipeline. Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations. Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Compugen Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027 Trial-in-progress poster on MAIA-ovarian presented at the ESMO Gynaecological Cancers Congress 2026, reinforcing the biological and clinical rationale for evaluating COM701 in platinum-sensitive ovarian cancer Partner AstraZeneca presented new data at ASCO 2026, including the first overall survival readout from the GEMINI-Hepatobiliary study in first-line biliary tract cancer Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned Solid financial position with cash runway expected to fund operations into 2029 HOLON, Israel, Aug. 3, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today reported financial results for the second quarter of 2026 and provided a corporate update. "Q2 2026 reflects continued execution across the business," said Eran Ophir, Ph.D., President and CEO of Compugen. "Our MAIA-ovarian trial in platinum-sensitive ovarian cancer remains on track for the interim analysis with median progression-free survival data expected by the first quarter of 2027, which would mark a potential inflection point for COM701 in a patient population with a significant unmet need. Our partnered programs also advanced during the quarter, with AstraZeneca initiating an additional Phase 3 trial with rilvegostomig and presenting new rilvegostomig data at ASCO 2026, and the Gilead-partnered GS-0321 Phase 1 trial progressing as planned. With cash runway expected into 2029, we believe we are well positioned to advance our immuno-oncology pipeline." COM701 Compugen continues to advance MAIA-ovarian, its sponsored, randomized, placebo-controlled adaptive platform trial evaluating COM701, a potential first-in-class anti-PVRIG antibody, as maintenance monotherapy in patients with second- and third-line relapsed platinum-sensitive ovarian cancer, a setting with no approved treatment option. The Company anticipates the interim analysis with median progression-free survival data by the first quarter of 2027. During the quarter, Compugen presented a trial-in-progress poster on MAIA-ovarian at the ESMO Gynaecological Cancers Congress in Copenhagen. The poster underscored the strong biological and clinical rationale for evaluating COM701 in this population, including the differentiated biology of the PVRIG pathway versus other checkpoints such as PD-1 and TIGIT, its high expression in ovarian cancer, and the durable responses previously observed with COM701 as mono- and combination therapy in heavily pre-treated platinum-resistant patients. The Company believes that clear prolongation of PFS in these patients versus placebo could inform a registration path for COM701 and establish it as a potential backbone for drug combinations. Clinically meaningful success could also enable a broader clinical development plan across earlier and later lines of ovarian cancer and other indications where clinical signals were previously observed. Rilvegostomig Rilvegostomig is a PD-1/TIGIT bispecific antibody being advanced by Compugen's partner AstraZeneca, the TIGIT component of which is derived from Compugen's fully owned COM902 program. At the 2026 ASCO Annual Meeting, AstraZeneca presented an updated analysis from the GEMINI-Hepatobiliary study of rilvegostomig in combination with chemotherapy in the first-line setting. This was the first overall survival readout for rilvegostomig, with median overall survival of 16.8 months, versus less than 13 months in historical first-line biliary tract cancer trials. The data showed encouraging efficacy together with a manageable safety profile in a setting of high unmet need, while longer follow-up and randomized data from the ongoing Phase 3 trial will ultimately be needed to validate these findings. AstraZeneca continues to advance rilvegostomig across its broad late-stage program in 12 ongoing Phase 3 trials, including the recently initiated trial of rilvegostomig in combination with Datroway in urothelial carcinoma. GS-0321 GS-0321, formerly known as COM503, is a potential first-in-class anti-IL-18 binding protein antibody licensed to Gilead that represents a novel antibody approach to harness cytokine biology for the treatment of cancer, potentially overcoming the limitations of direct cytokine administration. The ongoing Phase 1 dose-escalation trial continues to progress as planned. Early Pipeline Compugen continues to leverage Unigen™, its AI/ML-powered computational discovery platform, to identify novel drug targets and biological pathways grounded in human disease biology. Unigen has already discovered the targets of COM701, COM902, and GS-0321 and we remain committed to identifying and advancing the next generation of immuno-oncology innovation. Second Quarter 2026 Financial Highlights Cash: As of June 30, 2026, Compugen had approximately $125.3 million in cash, cash equivalents, short-term bank deposits, and investment in marketable securities. Compugen expects that its cash and cash-related balances will be sufficient to fund its operating plans into 2029. This does not include any additional cash inflows. The Company has no debt. Revenues for the second quarter of 2026 were approximately $2.6 million, compared to approximately $1.3 million for the comparable period in 2025. Revenues in the second quarters of 2026 and 2025 reflect the recognition of portions of both the upfront payment and the IND milestone payment from the license agreement with Gilead. R&D expenses for the second quarter of 2026 were approximately $6.3 million, compared to approximately $5.6 million in the second quarter of 2025. G&A expenses for the second quarter of 2026 were approximately $2.3 million, compared to approximately $2.2 million in the second quarter of 2025. Net loss for the second quarter of 2026 was approximately $7.0 million, or $0.07 per basic and diluted share, compared to a net loss of approximately $7.3 million, or $0.08 per basic and diluted share, in the second quarter of 2025. Full financial tables are included below. Conference Call and Webcast Information The Company will hold a conference call today, August 3, 2026, at 8:30 AM ET to review its second quarter 2026 results. To access the conference call by telephone, please dial 1-866-744-5399 from the United States, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Forward-Looking Statement This press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements regarding our expectations for COM701 MAIA-ovarian to have median progression-free survival data at the interim analysis by Q1 2027; statements regarding the biological and clinical rationale for evaluating COM701 in platinum-sensitive ovarian cancer and the potential of clear prolongation of PFS in these patients versus placebo to inform a registration path, serve as a backbone for combinations; statements regarding the potential clinical meaningful success of the MAIA-Ovarian trial to enable a broader clinical development across ovarian cancer and other indications; statements regarding AstraZeneca's advancement of its rilvegostomig program; statements regarding the advancement of Phase 1 trial for Gilead-partnered GS-0321; statements to the effect that our cash and cash-related balances will be sufficient to fund our operating plans into 2029. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: the clinical trials of any product candidates that Compugen, or any current or future collaborators, may develop may fail to satisfactorily demonstrate safety and efficacy to the FDA, and Compugen, or any collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates; Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen's approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; general market, political and economic conditions in the countries in which Compugen operates, including Israel; the effect of the evolving nature of the recent war in Israel; and Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value. These risks and other risks are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law. Company contact: Lindsey TrickettHead of Investor Relations and Corporate CommunicationsEmail: [email protected]: +1 (628) 241-0071 View original content:https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2026-results-302841059.html

HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on Monday, August 3, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following the live webcast, a replay will be available on the Company's website. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company Contact: Lindsey TrickettHead of Investor Relations and Corporate CommunicationsEmail: [email protected]: +1 (628) 241-0071 View original content:https://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-2026-results-on-monday-august-3-2026-302829393.html

This article first appeared on GuruFocus. Cash Balance: Approximately $134.9 million as of March 31, 2026. Revenue: Approximately $2.2 million for Q1 2026, compared to $2.3 million in Q1 2025. R&D Expenses: Approximately $6.9 million for Q1 2026, up from $5.8 million in Q1 2025. G&A Expenses: Approximately $2.3 million for Q1 2026, compared to $2.4 million in Q1 2025. Net Loss: Approximately $7.7 million or $0.08 per share for Q1 2026, compared to $7.2 million or $0.08 per share in Q1 2025. Cash Runway: Expected to fund operations into 2029. Warning! GuruFocus has detected 6 Warning Signs with CGEN. Is CGEN fairly valued? Test your thesis with our free DCF calculator. Release Date: May 18, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Compugen Ltd (NASDAQ:CGEN) is making significant progress with its fully owned clinical program, COM701, which has shown promising results in ovarian cancer treatment. The company has initiated the MAIA-ovarian adaptive platform trial to test COM701 as a maintenance therapy, with active patient enrollment across the United States, Israel, and France. Compugen Ltd (NASDAQ:CGEN) has a solid financial position with a cash runway expected to last into 2029, providing stability and flexibility for future developments. Partnership with AstraZeneca is progressing well, with multiple abstracts presented at the AACR Annual Meeting, reinforcing confidence in the rilvegostomig program. The Unigen discovery engine continues to be a valuable asset, having already discovered targets for COM701, COM902, and GS-0321, and is expected to identify more innovative programs. Revenues for the first quarter of 2026 were slightly lower than the comparable period in 2025, indicating potential challenges in revenue growth. Research and development expenses have increased, primarily due to higher clinical expenses related to the MAIA-ovarian trial and drug supply costs. The net loss for the first quarter of 2026 increased compared to the same period in 2025, reflecting ongoing financial challenges. The MAIA-ovarian trial is exploratory, and the full magnitude of benefit from COM701 is still uncertain, with benchmarks for control arm PFS ranging widely. There is no specific timeline or guidelines for disclosing future development candidates from the Unigen platform, which may lead to uncertainty about pipeline progress. Q: Can you provide more details on the data sets AstraZeneca will present at ASCO regarding rilvegostomig? A: Eran Ophir, President and CEO, explained that there are two data sets: one from the I-SPY trial testing rilvegostomig in adjuvant settings with Enhertu, and another from the GEMINI-Hepatobiliary trial in combination with chemotherapy. The focus will be on combinability and long-term effects, though specific expectations should be set cautiously. Q: How will future development candidates from the Unigen platform be disclosed? A: Eran Ophir stated that disclosure timing depends on the asset and its stage of derisking. The IL-18 binding protein antibody was disclosed early due to its preclinical out-licensing, but future disclosures will vary based on the asset's readiness and strategic considerations. Q: Is the MAIA-ovarian trial stratified by PD-L1 status, and how will interim data influence the trial design? A: Michelle Mahler, Chief Medical Officer, clarified that the trial is not stratified by PD-L1 status but by treatment line. Interim data in Q1 2027 could lead to trial adjustments, including adding arms, depending on the data and regulatory engagement. Q: What is the enrollment status for the MAIA-ovarian trial, and what are the benchmarks for the control arm PFS? A: Michelle Mahler noted that enrollment is on track for the interim analysis in Q1 2027. The control arm PFS benchmark is approximately 5.5 months, with a range from 3.8 to 5.8 months. The goal is to show a meaningful improvement in PFS with COM701. Q: How does the unique biology of PVRIG influence the MAIA-ovarian trial's design? A: Eran Ophir highlighted that PVRIG's unique biology allows COM701 to show responses across PD-L1 positive and negative patients, differentiating it from other checkpoints like TIGIT and PD-1. This influences the trial's design by not requiring PD-L1 stratification. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the company’s first-quarter earnings call, President and Chief Executive Officer Dr. Eran Ophir said 2026 is “shaping up to be a significant year” for Compugen as it advances COM701, its wholly owned antibody targeting PVRIG, and monitors progress on partnered assets with AstraZeneca and Gilead. → 3 Crucial Aerospace Component Makers That Analysts Love Compugen’s lead wholly owned clinical program, COM701, is being evaluated in the MAIA-ovarian adaptive platform trial as maintenance monotherapy compared with placebo in patients with relapsed platinum-sensitive ovarian cancer who responded to their most recent line of chemotherapy. Ophir said the company initiated the study based on prior data presented at ESMO, where pooled clinical data showed COM701, as monotherapy and in combinations, was well-tolerated and produced “consistent, durable responses” in heavily pretreated patients with platinum-resistant ovarian cancer. → 3 Stocks to Own If Gas Prices Keep Rising The company is now testing COM701 in an earlier ovarian cancer setting, with the rationale that patients may have lower tumor burden and a less compromised immune system, potentially improving the likelihood of benefit from COM701’s mechanism of action. Ophir said all clinical sites are open and enrolling across the United States, Israel and France. He said that gives the company confidence in its ability to complete enrollment on schedule for interim median progression-free survival data in the first quarter of 2027. → Peloton Stock Gives Back Gains After Upbeat Earnings Report Chief Medical Officer Dr. Michelle Mahler said during the question-and-answer session that Compugen is not currently commenting on specific enrollment numbers, but remains “on track” for the planned interim analysis. She said the study is stratified by second-line versus third-line treatment, not by PD-L1 status. Ophir added that prior clinical signals with COM701 have been seen in both PD-L1-positive and PD-L1-negative patients, saying PD-L1 stratification may not be the critical factor for the PVRIG-targeting approach. Mahler said the benchmark progression-free survival for the control arm, based on prior second- and third-line maintenance studies in similar untreated patient populations, is about 5.5 months, with a range from 3.8 months to 5.8 months. She said Compugen hopes to show “meaningful single agent clinical activity” and has hypothesized that a three-month or greater improvement over benchmark progression-free survival would be meaningful. Mahler also said the adaptive trial could allow for adjustments after the interim readout, including the possibility of adding arms, depending on the totality of the data and engagement with regulators on potential steps toward a pivotal trial. Compugen also highlighted progress by AstraZeneca on rilvegostomig, a bispecific antibody program connected to Compugen’s partnered pipeline economics. Ophir said AstraZeneca presented multiple rilvegostomig abstracts at the AACR annual meeting, including preclinical data supporting potential use as an immuno-oncology backbone for combinations and late-breaking data from the DESTINY-Gastric03 phase 2 trial. That trial evaluated rilvegostomig in combination with ENHERTU and chemotherapy as a first-line treatment for HER2-positive gastric cancers. Ophir said the data showed “promising antitumor activity” and supported the safety combinability of rilvegostomig. Ophir said AstraZeneca is advancing rilvegostomig in 11 phase 3 trials across multiple indications, including a recently opened gastric cancer trial in combination with a claudin 18.2 antibody-drug conjugate. He also said Compugen expects additional clinical data from AstraZeneca during the year, including at the upcoming ASCO meeting. In response to an analyst question, Ophir said two clinical datasets are expected at ASCO: one from the I-SPY trial evaluating rilvegostomig in an adjuvant setting with ENHERTU, and another from a German hepatobiliary study in combination with chemotherapy. He cautioned against setting expectations on behalf of AstraZeneca, but said safety and combinability would be important areas to watch. Compugen said AstraZeneca has previously estimated non-risk-adjusted peak annual revenue potential of more than $5 billion for rilvegostomig. Compugen is eligible for up to $995 million in additional regulatory and commercial milestone payments, plus mid-single-digit tiered royalties on sales. Ophir said GS-0321, formerly known as COM503, continues to progress as planned in an ongoing phase 1 dose-escalation trial. The asset is a potential first-in-class anti-IL-18 binding protein antibody licensed to Gilead. Compugen has received $90 million to date from Gilead for the program and remains eligible for up to $758 million in additional milestone payments, plus up to double-digit tiered royalties, according to the company. Ophir said GS-0321 reflects Compugen’s strategy of using its AI-powered computational discovery platform, Unigen, to identify novel immuno-oncology approaches. He said Unigen discovered the targets for COM701, COM902 and GS-0321. Chief Financial Officer David Silberman said Compugen ended the first quarter with about $134.9 million in cash equivalents, short-term bank deposits and investments in marketable securities as of March 31, 2026. The company said its cash runway, assuming no further cash inflows, is expected to fund operating plans into 2029. Ophir and Silberman both referenced a December 2025 transaction with AstraZeneca that brought in $65 million in non-dilutive capital through the monetization of a small portion of future rilvegostomig royalties. Revenue: First-quarter 2026 revenue was approximately $2.2 million, compared with approximately $2.3 million in the prior-year period. The revenue in both periods reflected recognition related to the upfront payment and R&D milestone payment from the Gilead license agreement. Research and development expenses: R&D expenses were approximately $6.9 million, up from approximately $5.8 million in the first quarter of 2025, mainly due to higher clinical expenses related to the MAIA-ovarian trial and drug supply costs. General and administrative expenses: G&A expenses were approximately $2.3 million, compared with approximately $2.4 million a year earlier. Net loss: The company reported a net loss of approximately $7.7 million, or $0.08 per basic and diluted share, compared with a net loss of approximately $7.2 million, or $0.08 per basic and diluted share, in the first quarter of 2025. Silberman said the company expects to use its runway to advance the COM701 MAIA-ovarian study, support the progression of GS-0321 with Gilead and continue investing in its early-stage pipeline. Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations. Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Compugen Q1 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for May 2026.

Compugen Ltd. (NASDAQ:CGEN) shares jumped more than 18% in premarket trading on Monday after the biotechnology company reported first-quarter revenue ahead of analyst expectations, despite posting a slightly wider-than-expected quarterly loss. The clinical-stage cancer immunotherapy company reported a quarterly loss of $0.08 per share for the period ended March 31, missing analyst estimates that had projected a loss of $0.07 per share. Revenue came in at $2.2 million, exceeding consensus expectations of $1.63 million. However, quarterly revenue was down 4% compared with $2.3 million reported in the first quarter of 2025. Compugen said revenue during the quarter reflected recognition of portions of both the upfront payment and the IND milestone payment tied to its licensing agreement with Gilead. Despite the earnings miss, investors appeared encouraged by stronger-than-expected revenue and continued advancement across the company’s clinical development programs. Compugen said enrollment in its COM701 MAIA-ovarian study is continuing across all participating clinical sites in the United States, Israel and France. The company remains on schedule to conduct an interim analysis during the first quarter of 2027. “Q1 2026 reflects continued execution across all of our programs in line with our strategic priorities,” said Eran Ophir, president and chief executive of Compugen. “With enrollment progressing across all COM701 MAIA-ovarian trial sites, we remain on track for having the median progression-free survival at the interim analysis by Q1 2027, a key potential inflection point for COM701 as a maintenance therapy in a patient population with significant unmet medical need and no current standard of care.” Research and development expenses increased to $6.9 million from $5.8 million a year earlier, primarily driven by higher clinical trial spending related to the MAIA-ovarian program and increased drug supply costs. General and administrative expenses edged slightly lower to $2.3 million from $2.4 million. Compugen reported total cash, cash equivalents, short-term bank deposits and marketable securities of approximately $134.9 million as of March 31, 2026. The company said its current financial resources are expected to support operations through 2029 based on existing development plans. Compugen also noted that partner AstraZeneca is continuing development of rilvegostomig across 11 ongoing Phase 3 studies, while the Phase 1 trial of GS-0321 under its partnership with Gilead Sciences is progressing as planned. Compugen stock price